Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma | Zendy

Mark P. Chao | Zendy; Ash A. Alizadeh | Zendy; Chad Tang | Zendy; June H. Myklebust | Zendy; Bindu Varghese | Zendy; Saar Gill | Zendy; Max Jan | Zendy; C. Adriel | Zendy; Charles K. F. Chan | Zendy; Brent Tan | Zendy; Christopher Y. Park | Zendy; Feifei Zhao | Zendy; Holbrook E. Kohrt | Zendy; Raquel Malumbres | Zendy; Javier Briones | Zendy; Randy D. Gascoyne | Zendy; Izidore S. Lossos | Zendy; Ronald Levy | Zendy; Irving L. Weissman | Zendy; Ravindra Majeti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

Author(s) -

Mark P. Chao,

Ash A. Alizadeh,

Chad Tang,

June H. Myklebust,

Bindu Varghese,

Saar Gill,

Max Jan,

C. Adriel,

Charles K. F. Chan,

Brent Tan,

Christopher Y. Park,

Feifei Zhao,

Holbrook E. Kohrt,

Raquel Malumbres,

Javier Briones,

Randy D. Gascoyne,

Izidore S. Lossos,

Ronald Levy,

Irving L. Weissman,

Ravindra Majeti

Publication year - 2010

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2010.07.044

Subject(s) - rituximab , cd47 , lymphoma , monoclonal antibody , antibody , immunology , cd20 , cancer research , biology , monoclonal antibody therapy , blocking antibody , medicine

Monoclonal antibodies are standard therapeutics for several cancers including the anti-CD20 antibody rituximab for B cell non-Hodgkin lymphoma (NHL). Rituximab and other antibodies are not curative and must be combined with cytotoxic chemotherapy for clinical benefit. Here we report the eradication of human NHL solely with a monoclonal antibody therapy combining rituximab with a blocking anti-CD47 antibody. We identified increased expression of CD47 on human NHL cells and determined that higher CD47 expression independently predicted adverse clinical outcomes in multiple NHL subtypes. Blocking anti-CD47 antibodies preferentially enabled phagocytosis of NHL cells and synergized with rituximab. Treatment of human NHL-engrafted mice with anti-CD47 antibody reduced lymphoma burden and improved survival, while combination treatment with rituximab led to elimination of lymphoma and cure. These antibodies synergized through a mechanism combining Fc receptor (FcR)-dependent and FcR-independent stimulation of phagocytosis that might be applicable to many other cancers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research